Gilead Sciences, Inc. (NASDAQ: GILD)
Gilead Sciences, Inc. (GILD), a biopharmaceutical company recently announced topline results from four Phase 3 clinical studies. “The Astral studies (1-4) evaluate once-daily, fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF) with velpatasvir (VEL), an investigational pangenotypic NS5A inhibitor, for the treatment of genotype 1-6 chronic hepatitis C virus (HCV) infection. Business Wire
Gilead Sciences, Inc. Chief Scientific Officer’s Comments
“The ASTRAL study results demonstrate that a 12-week course of therapy with the first fixed-dose combination of two pan-genotypic compounds can provide high cure rates for patients with all HCV genotypes,” said Norbert Bischofberger, Ph.D., Executive Vice President of Research and Development and Chief Scientific Officer at Gilead. “We are pleased to have now brought forward our second single tablet regimen for HCV infection that complements Harvoni, our first single tablet regimen approved specifically for patients with genotype 1 infection and which could eliminate the need for HCV genotype testing. We look forward to advancing the regulatory submissions for the SOF/VEL fixed-dose combination.” Business Wire
GILD Technical Analysis
Taking a look at GILD’s daily chart we notice that the stock has been on a decline for the past few months. The stock has been on a pattern of putting in lower highs dating back to June 23rd. On June 23rd, the stock hit highs of $122.40. The next spike up on August 3rd hit highs of $120.17 followed by the spike up on August 18th of $117.70 and finally the last spike up on September 17th of $113.31. On all of these occasions, the stock continued to move lower. Following the August 18th spike, the stock began a freefall and dropped all the way to $86; only $0.05 away from its 52 week low in only four trading days, equivalent to a 27% drop in price. As we can see, there is extreme volatility in this stock. The stock on Friday was trading at $100 so it will be interesting to see if the stock can hold the $100 price level. If the stock dips below the $100 price level it may be time to go short and use $100 as your stop loss.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The companys products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with Bristol-Myers Squibb Company, Janssen R&D Ireland, and Japan Tobacco Inc. to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California. Yahoo Finance